Compare LXU & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LXU | URGN |
|---|---|---|
| Founded | 1968 | 2004 |
| Country | United States | United States |
| Employees | 513 | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 922.1M |
| IPO Year | 2006 | 2016 |
| Metric | LXU | URGN |
|---|---|---|
| Price | $15.08 | $21.46 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | $14.63 | ★ $29.29 |
| AVG Volume (30 Days) | ★ 1.9M | 619.6K |
| Earning Date | 04-29-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 225.93 | N/A |
| EPS | ★ 0.34 | N/A |
| Revenue | ★ $615,208,000.00 | $1,128,000.00 |
| Revenue This Year | $10.78 | $127.17 |
| Revenue Next Year | N/A | $73.82 |
| P/E Ratio | $41.62 | ★ N/A |
| Revenue Growth | ★ 17.77 | N/A |
| 52 Week Low | $4.92 | $3.42 |
| 52 Week High | $17.22 | $30.00 |
| Indicator | LXU | URGN |
|---|---|---|
| Relative Strength Index (RSI) | 56.56 | 61.05 |
| Support Level | $7.92 | $21.40 |
| Resistance Level | $15.66 | $22.29 |
| Average True Range (ATR) | 0.92 | 1.16 |
| MACD | -0.22 | 0.44 |
| Stochastic Oscillator | 49.61 | 81.48 |
LSB Industries Inc is engaged in the manufacturing and sale of chemical products in the United States. The company manufactures and sells chemical products for the agricultural and industrial sectors. Its products include ammonia, fertilizer grade ammonium nitrate (AN and HDAN), and urea ammonia nitrate (UAN) for agricultural applications; high purity and commercial grade ammonia, sulfuric acids, concentrated, blended, and regular nitric acid, mixed nitrating acids, carbon dioxide, and diesel exhaust fluid for industrial applications; and industrial grade AN (LDAN) and AN solutions for mining applications. Its products are sold through distributors and directly to end customers throughout the United States and other parts of North America.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.